
DANIELE VERITTI



Curriculum Vitae
Europass



PERSONAL INFORMATION

Name / Surname **Daniele Veritti**

Address P.le Santa Maria della Misericordia 15
33100 Udine, Italy

Work phone +39.0432.559907

Fax +39.0432.559904

Mobile +39.3408014456

E-mail (personal) verittidaniele@gmail.com

E-mail (work) daniele.veritti@uniud.it

Citizenship Italian

Birthdate 29 december 1981

Sex M

CURRENT POSITION Associate professor

MED/30 Ophthalmology

**Physician, SOC Clinica Oculistica Udine – ASU FC P.O. Universitario
S. Maria della Misericordia Piazzale S. Maria della Misericordia, 15
33100 Udine, Italy**

Daniele VERITTI

ORCID iD

 <https://orcid.org/0000-0003-0148-5348>



DANIELE VERITTI

EDUCATION AND TRAINING

| | |
|---|------|
| European School for Advanced Studies in Ophthalmology | 2020 |
| Glaucoma Module Cornea Module | |
| Venice Ophthalmology Summer School | 2013 |
| Residency in Ophthalmology | 2012 |
| Dept. Of Ophthalmology, University of Udine, Italy <i>Dissertation: "Triple Therapy for Anti-VEGF Non-responders in Neovascular Age-Related Macular Degeneration. Ranibizumab, Juxtasclear Triamcinolone Acetonide and Photodynamic therapy with verteporfin".</i> First-class honours. | |
| European School for Advanced Studies in Ophthalmology | 2010 |
| Retinal Diseases Module: Medical Retina and Surgical Retina Lugano, Switzerland | |
| Medical license | 2008 |
| MD Official Register of Udine, Italy #5058. | |
| Doctor of Medicine (MD) degree | 2007 |
| University of Udine, Italy <i>Dissertation: "Posterior Juxtasclear Infusion of Modified Triamcinolone Acetonide Formulation For Refractory Diabetic Macular Edema. One-year Follow Up"</i> | |
| High school degree | 2000 |
| Liceo Scientifico "Luigi Magrini", Gemona del Friuli, Italy | |

PERSONAL SKILLS

| | |
|--------------------------|--|
| Mother Tongue | Italian |
| Foreign Languages | English. Understanding C1, Speaking B2, Writing C1 German. Understanding A2, Speaking A2, Writing A2 |
| Digital skills | Advanced user: information processing, content creation, security configuration. Good command of office suite (word processor, spread sheet, presentation software). Good command of statistical softwares (SPSS, MedCalc, CMA). |

DANIELE VERITTI

WORK EXPERIENCES

Associate Professor (06/F2; MED-30) Dept. Of Medicine, University of Udine.

01.10.2021-present

Visiting Professor. Department of Ophthalmology, Medical University Vienna, Vienna, Austria.

15.05.2020-15.09.2020

Physician, ASU FC P.O. Universitario S. Maria della Misericordia Piazzale S. Maria della Misericordia, 15 33100 Udine, Italy

05.03.2019-present

Assistant Professor (RTD-B) (06/F2; MED-30) Dept. Of Medicine, University of Udine.

05.03.2019-30.09.2021

Physician, SOC Clinica Oculistica, Azienda Ospedaliero-Universitaria Integrata Santa Maria della Misericordia di Udine.

01.12.2014-30.09.2018

Assistant Professor (RTD-A) (06/F2; MED-30) Dept. Of Medicine, University of Udine. 01.10.2013-30.09.2018

PUBLICATION METRICS

Scopus (06.04.2022)

Pubblicazioni originali su riviste indicizzate: 67

Citazioni: 845

H-index: 15

Google Scholar (06.04.2022)

Citazioni: 1224

H-index: 19

i10-index: 33

EDITORIAL POSTS

Associate editor

- Serving as Editorial board member of 6 Pubmed-indexed scientific journals.
- Serving as Scientific reviewer for the most relevant scientific journals in the field of Ophthalmology.

DANIELE VERITTI

TECHNOLOGICAL TRANSFER Patent

- Co-inventor, national patent (102017000116091), international patent (WO2019/076815). Tonometer cone.

SPONSORED RCT Sub-investigator, >20 sponsored RCT

INVITED SPEAKER 2008-present: invited speaker at over 150 scientific congresses/ meetings/courses.

CLINICAL EXPERIENCE Surgical experience

- Anterior segment procedures (first): >1500
 - PHACO+IOL: 1300
- Posterior segment procedures (second): >500
- Laser procedures (SLT, YAG, PDT, PRP): >500
- Intravitreal injections: >2000

FINAL DECLARATIONS

- *I hereby authorize the use of my personal data, according to DLGS 196/2003 and GDPR (UE 2016/679).*

- *I confirm I gained experience in the conduction of clinical trials in accordance with the principles of Good Clinical Practice.*

Daniele Veritti